Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.

Bryant G, Wang L, Mulholland DJ.

Int J Mol Sci. 2017 Jul 17;18(7). pii: E1542. doi: 10.3390/ijms18071542. Review.

2.

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ.

Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18. No abstract available.

3.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

4.

Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.

Hinduja A, Limaye K, Ravilla R, Sasapu A, Papanikolaou X, Wei L, Torbey M, Waheed S.

PLoS One. 2016 Nov 30;11(11):e0166627. doi: 10.1371/journal.pone.0166627. eCollection 2016. Erratum in: PLoS One. 2017 Mar 30;12 (3):e0175218.

5.

Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Rajkumar SV.

Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402. Review.

6.

Stem cell transplantation for multiple myeloma: current and future status.

Giralt S, Bensinger W.

Leuk Suppl. 2013 May;2(Suppl 1):S10-4. doi: 10.1038/leusup.2013.3. Epub 2013 May 8. Review.

7.

Multiple Myeloma: Diagnosis and Treatment.

Rajkumar SV, Kumar S.

Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007. Review.

8.

FOXM1 is a therapeutic target for high-risk multiple myeloma.

Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S.

Leukemia. 2016 Apr;30(4):873-82. doi: 10.1038/leu.2015.334. Epub 2015 Dec 9.

9.

Myeloma today: Disease definitions and treatment advances.

Rajkumar SV.

Am J Hematol. 2016 Jan;91(1):90-100. doi: 10.1002/ajh.24236. Review. Erratum in: Am J Hematol. 2016 Sep;91(9):965.

10.

Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.

Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M.

PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. eCollection 2015.

11.

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Bolomsky A, Hose D, Schreder M, Seckinger A, Lipp S, Klein B, Heintel D, Ludwig H, Zojer N.

J Hematol Oncol. 2015 Feb 8;8:10. doi: 10.1186/s13045-014-0105-1.

12.

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B.

Leukemia. 2015 May;29(5):1195-201. doi: 10.1038/leu.2015.15. Epub 2012 Feb 2.

13.

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma.

Al-Mansour Z, Ramanathan M.

Adv Hematol. 2014;2014:652395. doi: 10.1155/2014/652395. Epub 2014 Nov 24. Review.

14.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS.

Oncotarget. 2014 Nov 15;5(21):10237-50.

15.

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.

16.

The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Orlowski RZ.

Oncology (Williston Park). 2011 Nov 15;25 Suppl 2:56-64. Review.

17.

A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.

Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R, van Duin M, Gregory WM, Davies FE, Brewer D, Hose D, Sonneveld P, Morgan GJ.

Leuk Lymphoma. 2015 Mar;56(3):594-601. doi: 10.3109/10428194.2014.911863. Epub 2014 Aug 19.

18.

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.

19.
20.

Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.

Greenberg AJ, Walters DK, Kumar SK, Rajkumar SV, Jelinek DF.

Eur J Haematol. 2013 Dec;91(6):504-13. doi: 10.1111/ejh.12192. Epub 2013 Sep 17.

Supplemental Content

Support Center